

A COLLABORATIVE PEDIATRIC CANCER RESEARCH AWARDS PROGRAM



OPEN HANDS
OVERFLOWING HEARTS



INFINITE
LOVE for KIDS
FIGHTING CANCER

A Collaborative Pediatric Cancer Research Awards Program streamlines the grant process for researchers, reviewers, and organizations. It is like the Common Application that the Ivy League schools use. Members include Rally Foundation for Childhood Cancer Research (Rally), The Truth 365, Arms Wide Open Childhood Cancer Foundation, Open Hands Overflowing Hearts, and Infinite Love for Kids Fighting Cancer; national nonprofit organizations dedicated to eliminating childhood cancer through innovative research in pediatric oncology. Members of the Collaborative may choose to co-fund or individually fund a grant. Last year, the Collaborative awarded \$3 million through 55 research grants. Each organization provides its own funding for grants it selects to fund and should be recognized as the donor. The Collaborative should not be recognized as a donor. Rally is the administrator of the Collaborative and the grants.

2020 POSTDOCTORAL AND CLINICAL RESEARCH FELLOW LETTER OF INTENT

LETTER OF INTENT

Application Opens
September 10, 2019
10:00 AM EST

<https://proposalcentral.com>

Due October 9, 2019
by 2:00 PM EST

FULL APPLICATION

For those invited to apply
based on Letter of Intent.

Application Opens
December 4, 2019
10:00 AM EST

Due January 15, 2020
by 2:00 PM EST

NOTICE OF AWARD

All researchers will be notified of
awards by April 30, 2020

START OF GRANT TERM

All funded grants will start
on July 1, 2020.

THE COLLABORATIVE INVITES LETTERS OF INTENT

for funding of childhood cancer projects in the following areas:

- Basic Science Research
- Clinical Translational Research
- Quality of Life, Survivorship and Palliative Care Studies
- Alternative Therapy Studies (using natural agents, integrated, personalized or holistic approaches)
- Designated funding for medulloblastoma, retinoblastoma, AML, lymphoma, Li-Fraumeni Syndrome (also known as SBLA Syndrome), and under-studied disease types; however, all types of childhood cancers will be considered.

FUNDING

Postdoctoral and Clinical Research Fellowship Grants are for one or two years of support. At the end of the award, you may apply for additional funding for the next grant cycle.

Each grant will be awarded up to \$50,000 per year.

All LOIs will be vetted through the competitive peer-review process. Based on scores, a limited number of applicants, whose LOIs are deemed most meritorious, will be invited to submit full research proposals to be considered for the available grants. All LOI applicants will receive an email on or before December 3, 2019, notifying them of the status of their application. The full application submission process will open December 4, 2019.

LETTER OF INTENT (LOI) SUBMISSION PROCESS

All interested fellows must complete the online LOI application sections following the guidelines below:

Title Page

Project Title is limited to 75 characters.

Project Summary

Layman's Summary suitable for general audience limited to 2,000 characters or less.

Scientific Abstract suitable for technical audience limited to 2,000 characters or less.

Brief description, 1,000 characters or less, of the applicant's major research interests and expertise.

Brief description, 1,000 characters or less, of the Postdoctoral and Clinical Research Fellow's mentor's major research areas and expertise.

Disease Type, Disease Area, and Research Area (select all that apply).

LOI TEMPLATE AND REQUIRED ATTACHMENTS

Biographical Sketch formatted to 2017 NIH guidelines.

Career plan, limited to half a page, describing applicant's career plan in pediatric oncology.

Applicant's Department Head and primary mentor letters of support.

Letter of Intent (limited to two and a half pages including header on first page) must include a Scientific Abstract providing a clear, concise overview of the proposed cancer research project, limited to half a page, and state the Specific Aims, Rationale and Approach, Innovation and Potential for Translational Application, and Future Patient Benefit.

Relevant references must be attached and are limited to one page.

IF YOU HAVE QUESTIONS, PLEASE CONTACT:

Leigh Anna Lang

Email: leighanna@rallyfoundation.org

Phone: 404-847-1270

A COLLABORATIVE PEDIATRIC CANCER RESEARCH AWARDS PROGRAM



OPEN HANDS
OVERFLOWING HEARTS



INFINITE
LOVE for KIDS
FIGHTING CANCER

A Collaborative Pediatric Cancer Research Awards Program streamlines the grant process for researchers, reviewers, and organizations. It is like the Common Application that Ivy League schools use. Members include Rally Foundation for Childhood Cancer Research (Rally), The Truth 365, Arms Wide Open Childhood Cancer Foundation, Open Hands Overflowing Hearts, and Infinite Love for Kids Fighting Cancer; national nonprofit organizations dedicated to eliminating childhood cancer through innovative research in pediatric oncology. Members of the Collaborative may choose to co-fund or individually fund a grant. Last year, the Collaborative awarded \$3 million in 55 research and fellowship grants. Each organization provides its own funding for grants it selects to fund and should be recognized as the donor. The Collaborative should not be recognized as a donor. Rally is the administrator of the Collaborative and the grants.

2020 YOUNG INVESTIGATOR AND INDEPENDENT INVESTIGATOR LETTER OF INTENT

LETTER OF INTENT

Application Opens
September 10, 2019
10:00 AM EST

<https://proposalcentral.com>

Due October 9, 2019
by 2:00 PM EST

FULL APPLICATION

For those invited to apply
based on Letter of Intent.

Application Opens
December 4, 2019
10:00 AM EST

Due January 15, 2020
by 2:00 PM EST

NOTICE OF AWARD

All researchers will be notified of
awards by April 30, 2020

START OF GRANT TERM

All funded grants will start
on July 1, 2020.

THE COLLABORATIVE INVITES LETTERS OF INTENT

for funding of childhood cancer projects in the following areas:

- Basic Science Research
- Clinical Translational Research
- Quality of Life, Survivorship and Palliative Care Studies
- Alternative Therapy Studies (using natural agents, integrated, personalized or holistic approaches)
- Designated funding for medulloblastoma, retinoblastoma, AML, lymphoma, Li-Fraumeni Syndrome (also known as SBLA Syndrome), and under-studied disease types; however, all types of childhood cancers will be considered.

FUNDING

Young Investigator and Independent Investigator Grants are for one or two years of support. At the end of the award, you may apply for additional funding for the next grant cycle. Young Investigators must be no more than five years post fellowship.

Each grant will be awarded up to \$50,000 per year.

All LOIs will be vetted through the competitive peer-review process. Based on scores, a limited number of applicants, whose LOIs are deemed most meritorious, will be invited to submit full research proposals to be considered for the available grants. All LOI applicants will receive an email on or before December 3, 2019, notifying them of the status of their application. The full application submission process will open December 4, 2019.

LETTER OF INTENT (LOI) SUBMISSION PROCESS

All interested investigators must complete the online LOI application sections following the guidelines below:

Title Page

Project Title is limited to 75 characters.

Project Summary

Layman's Summary suitable for general audience limited to 2,000 characters or less.

Scientific Abstract suitable for technical audience limited to 2,000 characters or less.

Brief description, 1,000 characters or less, of the applicant's major research interests and expertise.

Disease Type (select all that apply).

Disease Area (select all that apply).

Research Area (select all that apply).

LOI TEMPLATE AND REQUIRED ATTACHMENTS

Biosketch formatted to 2017 NIH guidelines.

Applicant's Department Head letter of support (Young Investigators only).

Letter of Intent (limited to two and a half pages including header on first page) must include a Scientific Abstract providing a clear, concise overview of the proposed cancer research project, limited to half a page, and state the Specific Aims, Rationale and Approach, Innovation and Potential for Translational Application, and Future Patient Benefit.

Relevant references must be attached and are limited to one page.

IF YOU HAVE QUESTIONS, PLEASE CONTACT:

Leigh Anna Lang

Email: leighanna@rallyfoundation.org

Phone: 404-847-1270

A COLLABORATIVE PEDIATRIC CANCER RESEARCH AWARDS PROGRAM



OPEN HANDS
OVERFLOWING HEARTS



INFINITE
LOVE for KIDS
FIGHTING CANCER

A Collaborative Pediatric Cancer Research Awards Program streamlines the grant process for researchers, reviewers, and organizations. It is like the Common Application that Ivy League schools use. Members include Rally Foundation for Childhood Cancer Research (Rally), The Truth 365, Arms Wide Open Childhood Cancer Foundation, Open Hands Overflowing Hearts, and Infinite Love for Kids Fighting Cancer; national nonprofit organizations dedicated to eliminating childhood cancer through innovative research in pediatric oncology. Members of the Collaborative may choose to co-fund or individually fund a grant. Last year, the Collaborative awarded \$3 million in 55 research and fellowship grants. Each organization provides its own funding for grants it selects to fund and should be recognized as the donor. The Collaborative should not be recognized as a donor. Rally is the administrator of the Collaborative and the grants.

2020 CONSORTIUM LETTER OF INTENT

LETTER OF INTENT

Application Opens
September 10, 2019
10:00 AM EST

<https://proposalcentral.com>

Due October 9, 2019
by 2:00 PM EST

FULL APPLICATION

For those invited to apply
based on Letter of Intent

Application Opens
December 4, 2019
10:00 AM EST

Due January 15, 2020
by 2:00 PM EST

NOTICE OF AWARD

All researchers will be notified of
awards by April 30, 2020.

START OF GRANT TERM

All funded grants will start
on July 1, 2020.

THE COLLABORATIVE INVITES LETTERS OF INTENT

for funding of childhood cancer projects in the following areas:

- Basic Science Research
- Clinical Translational Research
- Quality of Life, Survivorship and Palliative Care Studies
- Alternative Therapy Studies (using natural agents, integrated, personalized or holistic approaches)
- Designated funding for medulloblastoma, retinoblastoma, AML, lymphoma, Li-Fraumeni Syndrome (also known as SBLA Syndrome), and under-studied disease types; however, all types of childhood cancers will be considered.

FUNDING

Consortium Grants, multi-institutional (three or more) collaborative research projects, may apply for one or two years of support up to \$100,000 per year.

At the end of the award, you may apply for additional funding for the next grant cycle.

All LOIs will be vetted through the competitive peer-review process. Based on scores, a limited number of applicants, whose LOIs are deemed most meritorious, will be invited to submit full research proposals to be considered for the available grants. All LOI applicants will receive an email on or before December 3, 2019, notifying them of the status of their application. The full application submission process will open December 4, 2019.

LETTER OF INTENT (LOI) SUBMISSION PROCESS

All interested Consortiums must complete the online LOI application sections following the guidelines below:

Title Page

Project Title is limited to 75 characters.

Project Summary

Layman's Summary suitable for general audience limited to 2,000 characters or less.

Scientific Abstract suitable for technical audience limited to 2,000 characters or less.

Brief description, 1,000 characters or less, of the applicant's major research interests and expertise.

Disease Type (select all that apply).

Disease Area (select all that apply).

Research Area (select all that apply).

LOI TEMPLATE AND REQUIRED ATTACHMENTS

Biosketch formatted to 2017 NIH guidelines.

Letter of Intent (limited to two and a half pages including header on first page) must include a Scientific Abstract providing a clear, concise overview of the proposed cancer research project, limited to half a page, and state the Specific Aims, Rationale and Approach, Innovation and Potential for Translational Application, and Future Patient Benefit.

Relevant references must be attached and are limited to one page.

IF YOU HAVE QUESTIONS, PLEASE CONTACT:

Leigh Anna Lang

Email: leighanna@rallyfoundation.org

Phone: 404-847-1270